We conclude that this SRC-Slug-TGFβ2 axis may contribute to chemotherapy resistance in an aggressive subpopulation of TNBC tumors, and targeting this pathway may help to improve outcomes for this aggressive breast cancer subtype. This evidence concerns the gene SRC and breast cancer.